The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

An interview with Dr. Nadine Tung and Dr. Dana Zakalik, co-chairs on ”Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO ...

The use of PARP inhibitors for the treatment of patients with BRCA1/2 mutations represents a milestone in genomically-directed therapies. Olaparib and talazoparib have shown to significantly extend ...

Hereditary breast cancer due to genetic mutations accounts for 5% to 10% of breast cancers. Breast cancer is the most ...

Inherited mutations in the gene BRCA2 significantly increase the risk of carriers to breast and ovarian cancers. BRCA2, a crucial player in the body's DNA repair system, aids in repairing damaged DNA.

Turning cancer’s weakness into a weapon: 20 years of PARP inhibitors and BRCA researchWhat is synthetic lethality? Synthetic lethality is a genetic concept where the loss of function in either one of ...

Mutations in the BRCA1 gene that are either inherited (germline) or acquired (somatic) might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its ...

Personalized Medicine. 2015;12(2):139-154. Compared to AstraZeneca, the other pharmaceutical companies have fewer Phase III trials running for their compounds. However, the approaches within these ...

Should screening for BRCA1/2 mutations be expanded to all women diagnosed with breast cancer? This is the recommendation put forth in recent guidelines from the American Society of Clinical Oncology ...